Egetis Therapeutics AB Company Description

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment.

Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment.

The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.

Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Egetis Therapeutics AB (publ)

Country	Sweden
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Nicklas Westerholm

Contact Details

Address: Klara Norra Kyrkogata 26 Stockholm, 111 22 Sweden
Phone	46 86 79 72 10
Website	egetis.com

Stock Details

Ticker Symbol	EGTX
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0003815604
SIC Code	2834

Key Executives

Name	Position
Nicklas Westerholm	Chief Executive Officer
Torsten Almén	Founder
Dr. Ingemar Lundström Ph.D.	Founder
Dr. Louis Joseph Ignarro Ph.D.	Founder
Associate Prof. Heidi Brurok	Founder
Dr. Rob Towart	Founder
Dr. Yilmaz Mahshid Ph.D.	Chief Financial Officer
Dr. Katayoun Welin-Berger Ph.D.	Vice President of Operations
Dr. Jacques Näsström M.B.A., MBA, Ph.D.	Chief Scientific Officer
Dr. Karl Hard Ph.D.	Vice President and Head of Investor Relations and Communication